|
|
B.Sc.: Pharmaceutical sciences - Faculty of Pharmacy - Misr University for Science Technology - 2008 |
M. Sc.:Pharmaceutical Chemistry - Faculty of Pharmacy - Cairo University - 2013 |
Ph. D.:Pharmaceutical Chemistry - Faculty of Pharmacy - Cairo University - 2016 |
|
|
Demonstrator :From 2009 To 2013 - Faculty of Pharmacy - Misr University for Science Technology |
Assistant Lecturer : From 2013 To 2016 - Faculty of Pharmacy - Misr University for Science Technology |
Lecturer : From 2016 To 2017, Faculty of Pharmacy - Misr University for Science Technology |
Lecturer : From 2017 to 2023 - Faculty of Pharmacy - Fayoum University |
Assistant Professor : From 2023 until now - Faculty of Pharmacy - Fayoum University |
|
|
Acting Vice-Dean for Post-graduate Studies. (3/11/2024 to Present) |
|
|
Pharmaceutical chemistry |
Molecular Design and Modeling |
|
|
Design, Synthesis and Molecular Modeling of Benzopyrone and Furobenzopyrone Analogues as Photochemotherapeutic Agents |
''Synthesis and Molecular Modeling of Benzopyrone and Furobenzopyrone Derivatives with Biological Activity'' |
|
|
Design, Synthesis, Biological Evaluation and Molecular Docking of Some Novel Benzopyrane-2-one Derivatives as Potential Selective Beta-1 Adrenergic Blockers . |
Design, synthesis, anticancer evaluation, and molecular modeling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. |
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization . |
Design, Synthesis and Mechanistic Study of New Benzenesulfonamide Derivatives as Anticancer and Antimicrobial Agents via Carbonic Anhydrase IX Inhibition. |
Design, Synthesis and Mechanistic Study of Novel Diarylpyrazole Derivatives as Anti-Inflammatory Agents with Reduced Cardiovascular Side Effects. |
New Multi-Targeted Antiproliferative Agents: Design and Synthesis of IC261-Based Oxindoles as Potential Tubulin, CK1 and EGFR Inhibitors. |
Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking . |
|